本品为天门冬氨酸钾盐和镁盐的混合物。其注射剂为L(+)-天冬氨酸与碳酸钾、氧化镁,经液相反应制成的无色澄明灭菌水溶液,每10ml内含L(+)-天冬氨酸以含鼠量计算为75.8mg,钾离子(K~(?))为103.3mg,镁离子(Mg~(2+))为33.7mg。本品早住1957年首先由法国研究,最初的动物试验发现能延长小鼠的游泳时间,引起了注意,后来德国、日本等相继研究,发现本品容易为人体吸收,与细胞亲和力强,有耐心肌缺氧的能力,经药理及临昧证明为治疗心血管系统疾病的优良药物,很快在欧美、日本等国相继投入生产,进入市场。国内已由无锡、天津的药厂研制成功,于1981年相继通过鉴定。药理试验表明,由于天冬氯酸与细胞有较强的亲和力,可以作为钾镁离子的载体进入细胞内,故对维持血钾、血镁,尤其是细胞内钾的含量具有优越性。本品对某些心脏疾患的作用比氯化钾更为有效和适宜,钾离子可以促进肌细胞除极化,维持肌收缩能力,从而 This product is a mixture of potassium aspartate and magnesium salts. The injection is L (+) - aspartic acid and potassium carbonate, magnesium oxide, made by the liquid phase of the clear sterile aqueous solution containing 10ml each containing L (+) - aspartic acid in rats Calculated as 75.8 mg, 103.3 mg of potassium ions (K?) And 33.7 mg of magnesium ions (Mg 2+). This product first lived in 1957, first by the French study, the first animal test found that mice can extend the swimming time, attracted attention, and later Germany, Japan and other studies have found that the product easily absorbed by the body, and cell affinity, there are Resistance to myocardial hypoxia, the pharmacology and Lin Mei proved to be an excellent drug for the treatment of cardiovascular diseases, and soon in Europe and the United States, Japan and other countries have been put into production, into the market. The domestic pharmaceutical companies have been successfully developed by Wuxi, Tianjin, in 1981 passed the appraisal. Pharmacological tests show that, aspartic acid and cells have strong affinity, as a carrier of potassium and magnesium ions into the cell, it is to maintain blood potassium, blood magnesium, especially intracellular potassium content has advantages. This product for some heart disease than potassium chloride more effective and appropriate, potassium ions can promote muscle cell depolarization, maintain muscle contraction ability, thus